Trade

with

Protalix BioTherapeutics Inc
(Amex: PLX)
AdChoices
2.29
-0.02
-0.87%
After Hours :
2.28
-0.01
-0.44%

Open

2.34

Previous Close

2.31

Volume (Avg)

199.81k (451.67k)

Day's Range

2.26-2.38

52Wk Range

2.05-5.30

Market Cap.

216.37M

Dividend Rate ( Yield )

-

Beta

0.85

Shares Outstanding

93.66M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 11.51M

    • Net Income

    • -27.79M

    • Market Cap.

    • 216.37M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -206.85

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.85

    • Forward P/E

    • -

    • Price/Sales

    • 14.71

    • Price/Book Value

    • -5.44

    • Price/Cash flow

    • -7.63

      • EBITDA

      • -23.58M

      • Return on Capital %

      • -37.87

      • Return on Equity %

      • -

      • Return on Assets %

      • -37.87

      • Book Value/Share

      • -0.42

      • Shares Outstanding

      • 93.66M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 6.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.17

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -12.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 39.40

            • 82.75

            • Pre-Tax Margin

            • -206.85

            • 39.38

            • Net Profit Margin

            • -206.85

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 214.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -1,850.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.03

              • 2.92

              • Quick Ratio

              • 2.69

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.42

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.05

                • 217.39

                • P/E Ratio 5-Year High

                • -38.47

                • 634.30

                • P/E Ratio 5-Year Low

                • -6.31

                • 124.82

                • Price/Sales Ratio

                • 14.58

                • 9.52

                • Price/Book Value

                • -5.39

                • 8.61

                • Price/Cash Flow Ratio

                • -7.63

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -37.87

                    (-37.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • 1.23

                  • 1.48

                  • Asset Turnover

                  • 0.18

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -27.12M
                  Operating Margin
                  -235.53
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.63
                  Ownership

                  Institutional Ownership

                  63.95%

                  Top 10 Institutions

                  55.50%

                  Mutual Fund Ownership

                  19.32%

                  Float

                  83.99%

                  5% / Insider Ownership

                  4.50%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Kaufmann Fund

                  •  

                    7,325,197

                  • 0.00

                  • 7.83

                  • Allianz Biotechnologie

                  •  

                    2,142,105

                  • -56.35

                  • 2.45

                  • Federated Kaufmann Small Cap Fund

                  •  

                    1,168,970

                  • -11.87

                  • 1.25

                  • BlackRock Health Sciences Opps Port

                  •  

                    1,155,326

                  • 0.00

                  • 1.23

                  • AST Federated Aggressive Growth

                  •  

                    1,055,300

                  • 0.00

                  • 1.13

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    975,842

                  • 0.00

                  • 1.04

                  • ZI BlackRock Global Fds Wld Health Sci

                  •  

                    437,574

                  • 0.00

                  • 0.47

                  • I.B.I Tel Aviv 75 Basket

                  •  

                    248,050

                  • -4.99

                  • 0.27

                  • Harbor International Growth Fund

                  •  

                    245,344

                  • 19.48

                  • 0.26

                  • FCP OP MEDICAL BioHealthTrends

                  •  

                    224,924

                  • 46.13

                  • 0.24

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Federated Global Inv Mgmt Corp

                  •  

                    9,942,841

                  • +594.34%

                  • 10.62

                  • Baillie Gifford & Co Limited.

                  •  

                    6,407,588

                  • +8.93%

                  • 6.85

                  • Allianz Global Investors

                  •  

                    5,056,168

                  • -17.51%

                  • 5.40

                  • Allianz Global Investors U.S. LLC

                  •  

                    2,142,105

                  • -56.35%

                  • 2.45

                  • Camber Capital Management LLC

                  •  

                    2,000,000

                  • 0.00%

                  • 2.14

                  • BlackRock Advisors LLC

                  •  

                    1,794,355

                  • +0.09%

                  • 1.92

                  • Dafna Capital Management LLC

                  •  

                    1,178,440

                  • 0.00%

                  • 1.26

                  • Fidelity Management and Research Company

                  •  

                    1,066,785

                  • -6.98%

                  • 1.14

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Protalix BioTherapeutics, Inc. was incorporated in Florida on April 1992. The Company and its wholly-owned subsidiary, Protalix Ltd. operate as biopharmaceutical companies focused on the development and commercialization of recombina...morent therapeutic proteins based on the Company’s proprietary ProCellEx protein expression system or ProCellEx. The Company’s product development candidate is prGCD for the treatment of Gaucher disease, which the Company is developing using its ProCellEx protein expression system. Using its ProCellEx system, it is developing a pipeline of proprietary and biosimilar or ‘generic’ versions of recombinant therapeutic proteins based on its plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms o...moref action. The Company’s initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the fields in which it operates is intense and expected to increase. As of December 31, 2013 the Company holds 49 patents. The testing, manufacture, distribution, advertising and marketing of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.lessless

                  Key People

                  Dr. David Aviezer,PhD

                  CEO/Director/President

                  Moshe Manor

                  CEO/Director/President

                  Shlomo Yanai

                  Chairman of the Board/Director

                  Yossi Maimon

                  CFO/Chief Accounting Officer/Secretary/Treasurer/Vice President

                  Dr. Yoseph Shaaltiel,PhD

                  Director/Executive VP, Divisional

                  • Protalix BioTherapeutics Inc

                  • 2 Snunit Street

                  • Carmiel, 20100

                  • USA.Map

                  • Phone: +972 49889488

                  • Fax: -

                  • protalix.com

                  Incorporated

                  1992

                  Employees

                  260

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: